Dr. Boris Gershman, MD

Dr. Gershman practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Gershman's NPI, 1013177518, was assigned on June 10, 2008. Dr. Gershman graduated from Perelman School of Med at the University of Pennsylvania in 2008. Dr. Gershman holds Rhode Island license MD15411.

Dr. Gershman's primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Gershman's primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Gershman is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Gershman to 2 more hospitals, 2 medical groups and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gershman practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Gershman's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Gershman's licenses on file in 2 states: Rhode Island and Massachusetts.

CMS data shows 879 Medicare services from Dr. Gershman across 13 procedure codes in 2024, for 356 Medicare patients. Medicare paid $69,925 for them.

CMS counts 356 Medicare patients who saw Dr. Gershman in 2024. The largest group is 65 to 74, with 175 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gershman's median patient age at 71, with 17% women.

In 2024, Dr. Gershman wrote 408 Medicare Part D claims for 163 patients. 99% of them were for generic drugs. CMS names the drug for 355 of them, across 6 drugs with 11 or more claims each, at $3,369 in total drug cost. In 2023, CMS named 341 claims across 6 drugs.

Dr. Gershman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gershman as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 94 papers to Dr. Gershman, published from 2013 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Prostatic Neoplasms, Kidney Neoplasms and Carcinoma, Renal Cell. Dr. Gershman has published most often in Urol Oncol. Dr. Gershman's most frequent co-authors are Stephen Anthony Boorjian, MD, Aria F. Olumi, FACS, MD and Bradley C. Leibovich, MD.

CMS Open Payments shows 64 general payments to Dr. Gershman from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. BK Medical Holding Company Inc. paid the most, $7,316.

Dr. Gershman graduated from Perelman School of Med at the University of Pennsylvania in 2008.